Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Takashi Omura is active.

Publication


Featured researches published by Takashi Omura.


Transplantation | 2000

Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720. Effect of monotherapy and combined treatment with conventional drugs

Hiroyuki Furukawa; Tomomi Suzuki; Maeng Bong Jin; Kenichiro Yamashita; Masahiko Taniguchi; Shinichiro Magata; Hiroto Ishikawa; Kenji Ogata; Hiroyuki Masuko; Tsuyoshi Shimamura; Moto Fukai; Takaaki Hayashi; Miri Fujita; Kazuro Nagashima; Takashi Omura; Akihiro Kishida; Satoru Todo

BACKGROUND The immunosuppressive effect and other properties of a novel immunosuppressant, FTY720, have been studied mostly in the experimental transplantation of various extrahepatic organs. In this experiment, we evaluated the antirejection potency and adverse effects of this agent on liver grafts using a canine liver transplantation model. METHODS Forty-eight orthotopic liver transplantations were performed by the standard technique under a veno-venous bypass. Liver recipients were divided into two studies: a single-dose study with FTY720 at various doses and a combined dose study with conventional immunosuppressants (cyclosporine or tacrolimus) alone and combined with FTY720. Survival, biochemical and hematological tests, blood levels of immunosuppressants, and postmortem histology were determined. RESULTS The median survival of untreated control animals was 9 days, whereas treatment with FTY720 at a dose of 0.1 mg/kg/day prolonged graft survival to 49.5 days. FTY720 at 1 mg/kg/day showed a slight but insignificant prolongation to 16 days, but when the dose was increased to 5 mg/kg/day, the graft was rejected at 10 days. The combination of FTY720, 0.1 mg/kg/day, with a subtherapeutic dose of cyclosporine, 5 mg/kg/ day, prolonged median animal survival from 40 days with cyclosporine alone to 74 days. A combination of FTY720 (0.1 mg/kg/day) with tacrolimus (0.5 mg/kg/ day) compromised animal survival, reducing survival from 83.5 days with tacrolimus alone to 30.5 days due to infectious complication and emaciation by overimmunosuppression. No evident drug-induced side effects were observed. CONCLUSIONS FTY720 has a potent immunosuppressive effect when used alone at 0.1 mg/kg/day in canine liver transplantation. FTY720 is a promising candidate for future clinical application in orthotopic liver transplantation.


Transplantation | 1996

Fifty-percent partial liver transplantation in the rat

Takashi Omura; Nancy L. Ascher; Jean C. Emond

Reduced-size liver transplantation in the rat has been useful in the study of hepatic regeneration. We describe a modified technique for partial liver transplantation in the rat using a 50% reduced-size graft. Male Lewis rats (RT1(1)), weighing 250 to 280 g, were used as donors and recipients. The harvested donor liver was placed in 4 degrees C cold saline and graft reduction was performed ex situ by resecting the left lateral lobe, the left portion of the median lobe, and the caudate lobes. The reduced graft was composed of the right portion of the median lobe and the right lobe, weighing 5.33 +/- O.58 g (53.6 +/- 2.2% of the donor liver before reduction, n=7). The recipient 1-week survival rate was 85.7%. The use of reduced livers permits the study of host responses to a deficient graft. This technique provides another choice of liver volume to be implanted and allows the study of regeneration of small-for-size livers more precisely in combination with more extensive graft reduction.


Journal of Surgical Research | 1997

Increased Immune Responses to Regenerating Partial Liver Grafts in the Rat

Takashi Omura; Tomonori Nakagawa; Henry B. Randall; Zhonghua Lin; Madeleine Huey; Nancy L. Ascher; Jean C. Emond


Transplantation | 1999

EFFECTS OF A NOVEL IMMUNOSUPPRESSANT, FTY720, ON HEART AND LIVER TRANSPLANTATIONS IN RATS.

Kenichiro Yamashita; Masaru Nomura; Megumi Takehara; Takashi Omura; Naoyuki Yanagida; Tomomi Suzuki; Tsuyoshi Shimamura; Akihiro Kishida; Hiroyuki Furukawa; Satoru Todo


Transplantation | 2000

PERMISSIVE LIMIT OF GRAFT SIZE FOR SUCCESSFUL LIVING DONOR LIVER TRANSPLANTATION IN ADULTS.: Abstract# 781 Poster Board #-Session: P38-III

Hiroyuki Furukawa; Akihiro Kishida; Takashi Omura; Michiaki Matsushita; T Kamiyama; Maeng Bong Jin; S. Todo


Transplantation | 2000

INHIBITION OF TYPE II PHOSPHOLIPASE A2 BY LY-329722 ATTENUATES ISCHEMIA-REPERFUSION INJURY OF THE LIVER.: Abstract# 1014

Kenji Ogata; Maeng Bong Jin; Masahiko Taniguchi; Tomomi Suzuki; Tsuyoshi Shimamura; Schinichirou Magata; Hiroyuki Masuko; Hiroto Ishikawa; Moto Fukai; Takashi Omura; Akihiro Kishida; Hiroyuki Furukawa; Satoru Todo


Transplantation | 2000

COMBINATION THERAPY OF CTLA4IG AND FTY720 COMPLETELY PREVENT THE DEVELOPMENT OF OBLITERATIVE BRONCHIOLITIS AND RESPIRATORY EPITHERIAL INJURY IN A MURINE AIRWAY MODEL.: Abstract# 728

Katsuhito Konishi; Masaaki Murakami; Manabu Inobe; Akira Yamada; Hayato Echizenya; Kenichiro Yamashita; Masaru Nomura; Takashi Omura; Satoru Todo; Toshimitsu Uede


Transplantation | 2000

PROTECTIVE EFFECT OF ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST ON ISCHEMIA AND REPERFUSION INJURY OF THE LIVER.: Abstract# 64

Hiroyuki Masuko; Hiroyuki Horiuchi; Tomomi Suzuki; Masahiko Taniguchi; Maeng Bong Jin; Tsuyoshi Shimamura; Moto Fukai; J Iida; S Magata; Kenji Ogata; Hiroto Ishikawa; Takashi Omura; Akihiro Kishida; Hiroyuki Furukawa; Satoru Todo


Transplantation | 2000

LONG TERM LIVER GRAFT ACCEPTANCE WITH AN NOVEL ADENOVIRUS MEDIATED CD40IgG GENE TRANSFER ON RAT.: Abstract# 643

Masaru Nomura; Kenichiro Yamashita; Masaaki Murakami; Megumi Takehara; Katsuhito Konishi; Hayato Echizenya; Naoyuki Yanagida; Zhao Xu-Dong; Takashi Omura; Akihiro Kishida; Hiroyuki Furukawa; Toshimitu Uede; Satoru Todo


Transplantation | 1999

Adult Living Related Liver Transplantation: Indication and Strategy

Hiroyuki Furukawa; Akihiro Kishida; Takashi Omura; Michiaki Matsushita; S. Todo

Collaboration


Dive into the Takashi Omura's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hiroyuki Furukawa

Asahikawa Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Masahiko Taniguchi

Asahikawa Medical University

View shared research outputs
Top Co-Authors

Avatar

S. Todo

University of Pittsburgh

View shared research outputs
Researchain Logo
Decentralizing Knowledge